Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α

Cancer Cell

Volumn 14, Issue 2, 2008, Pages 180-192

  Zunder, Eli R ^a   Knight, Zachary A ^a   Houseman, Benjamin T ^b   Apsel, Beth ^a   Shokat, Kevan M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CELLCYCLE; CHEMBIO

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P 110ALPHA; PIK 75; PIK 90; PIK 93; PP 110; PROTEIN KINASE INHIBITOR; PW 12; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE;

PYRONIA TITHONUS;

EID: 48449091227     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.06.014     Document Type: Article

References (61)

1. Alaimo P.J., Knight Z.A., and Shokat K.M. Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg. Med. Chem. 13 (2005) 2825-2836
2. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843
3. Balla A., Tuymetova G., Toth B., Szentpetery Z., Zhao X., Knight Z.A., Shokat K., Steinbach P.J., and Balla T. Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling. Biochemistry 47 (2008) 1599-1607
4. Bishop A.C., Ubersax J.A., Petsch D.T., Matheos D.P., Gray N.S., Blethrow J., Shimizu E., Tsien J.Z., Schultz P.G., Rose M.D., et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407 (2000) 395-401
5. Boschelli D.H., Wang Y.D., Ye F., Wu B., Zhang N., Dutia M., Powell D.W., Wissner A., Arndt K., Weber J.M., and Boschelli F. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J. Med. Chem. 44 (2001) 822-833
6. Branca M.A. Multi-kinase inhibitors create buzz at ASCO. Nat. Biotechnol. 23 (2005) 639
7. Brugge J., Hung M.C., and Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 12 (2007) 104-107
8. Brugge J.S., Jarosik G., Andersen J., Queral-Lustig A., Fedor-Chaiken M., and Broach J.R. Expression of Rous sarcoma virus transforming protein pp60v-src in Saccharomyces cerevisiae cells. Mol. Cell. Biol. 7 (1987) 2180-2187
9. Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence Jr. J.C., and Abraham R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15 (1996) 5256-5267
10. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
11. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102 (2005) 11011-11016
12. Chang H.W., Aoki M., Fruman D., Auger K.R., Bellacosa A., Tsichlis P.N., Cantley L.C., Roberts T.M., and Vogt P.K. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276 (1997) 1848-1850
13. Cosker K.E., and Eickholt B.J. Phosphoinositide 3-kinase signalling events controlling axonal morphogenesis. Biochem. Soc. Trans. 35 (2007) 207-210
14. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6 (2006) 184-192
15. Cutler N.S., Heitman J., and Cardenas M.E. STT4 is an essential phosphatidylinositol 4-kinase that is a target of wortmannin in Saccharomyces cerevisiae. J. Biol. Chem. 272 (1997) 27671-27677
16. Daub H., Specht K., and Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3 (2004) 1001-1010
17. Debnath J., Muthuswamy S.K., and Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30 (2003) 256-268
18. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116 (2006) 2695-2706
19. Fan Q.W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
20. Fruman D.A., Meyers R.E., and Cantley L.C. Phosphoinositide kinases. Annu. Rev. Biochem. 67 (1998) 481-507
21. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
22. Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281 (1998) 533-538
23. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., Nye E., Stamp G., Alitalo K., and Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129 (2007) 957-968
24. Hale B.G., and Randall R.E. PI3K signalling during influenza A virus infections. Biochem. Soc. Trans. 35 (2007) 186-187
25. Hayakawa M., Kaizawa H., Kawaguchi K., Ishikawa N., Koizumi T., Ohishi T., Yamano M., Okada M., Ohta M., Tsukamoto S., et al. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 15 (2007) 403-412
26. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Yamano M., Okada M., Ohta M., Tsukamoto S., Raynaud F.I., et al. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 2438-2442
27. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
28. Huang C.H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., Kinzler K.W., Vogelstein B., Gabelli S.B., and Amzel L.M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318 (2007) 1744-1748
29. Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., Ohta M., Jazag A., Guleng B., Tateishi K., et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65 (2005) 4562-4567
30. Isakoff S.J., Engelman J.A., Irie H.Y., Luo J., Brachmann S.M., Pearline R.V., Cantley L.C., and Brugge J.S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65 (2005) 10992-11000
31. Jimeno A., and Hidalgo M. Multitargeted therapy: can promiscuity be praised in an era of political correctness?. Crit. Rev. Oncol. Hematol. 59 (2006) 150-158
32. Kang S., Bader A.G., and Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA 102 (2005) 802-807
33. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125 (2006) 733-747
34. Knight Z.A., Feldman M.E., Balla A., Balla T., and Shokat K.M. A membrane capture assay for lipid kinase activity. Nat. Protoc. 2 (2007) 2459-2466
35. Kwon C.H., Luikart B.W., Powell C.M., Zhou J., Matheny S.A., Zhang W., Li Y., Baker S.J., and Parada L.F. Pten regulates neuronal arborization and social interaction in mice. Neuron 50 (2006) 377-388
36. Lim K.H., and Counter C.M. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8 (2005) 381-392
37. Liu Y., Shah K., Yang F., Witucki L., and Shokat K.M. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg. Med. Chem. 6 (1998) 1219-1226
38. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 (2003) 257-262
39. Mahon F.X., Deininger M.W., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., and Melo J.V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96 (2000) 1070-1079
40. Marone R., Cmiljanovic V., Giese B., and Wymann M.P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 1784 (2008) 159-185
41. Odorizzi G., Babst M., and Emr S.D. Phosphoinositide signaling and the regulation of membrane trafficking in yeast. Trends Biochem. Sci. 25 (2000) 229-235
42. Paling N.R., Wheadon H., Bone H.K., and Welham M.J. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J. Biol. Chem. 279 (2004) 48063-48070
43. Quintas-Cardama A., Kantarjian H., and Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 6 (2007) 834-848
44. Raynaud F.I., Eccles S., Clarke P.A., Hayes A., Nutley B., Alix S., Henley A., Di-Stefano F., Ahmad Z., Guillard S., et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67 (2007) 5840-5850
45. Rodgers E.E., and Theibert A.B. Functions of PI 3-kinase in development of the nervous system. Int. J. Dev. Neurosci. 20 (2002) 187-197
46. Rodriguez-Escudero I., Roelants F.M., Thorner J., Nombela C., Molina M., and Cid V.J. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochem. J. 390 (2005) 613-623
47. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
48. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
49. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
50. Shah N.P., and Sawyers C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22 (2003) 7389-7395
51. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
52. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
53. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
54. Stauffer F., Maira S.M., Furet P., and Garcia-Echeverria C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett. 18 (2008) 1027-1030
55. Stephens L., Williams R., and Hawkins P. Phosphoinositide 3-kinases as drug targets in cancer. Curr. Opin. Pharmacol. 5 (2005) 357-365
56. Tugendreich S., Perkins E., Couto J., Barthmaier P., Sun D., Tang S., Tulac S., Nguyen A., Yeh E., Mays A., et al. A streamlined process to phenotypically profile heterologous cDNAs in parallel using yeast cell-based assays. Genome Res. 11 (2001) 1899-1912
57. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
58. von Bubnoff N., Veach D.R., van der Kuip H., Aulitzky W.E., Sanger J., Seipel P., Bornmann W.G., Peschel C., Clarkson B., and Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105 (2005) 1652-1659
59. Walker E.H., Perisic O., Ried C., Stephens L., and Williams R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402 (1999) 313-320
60. Ward S.G., and Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3 (2003) 426-434
61. Zhao J.J., Liu Z., Wang L., Shin E., Loda M.F., and Roberts T.M. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. USA 102 (2005) 18443-18448